...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The American Journal of Cardiology >Meta-Analysis of Inclisiran for the Treatment of Hypercholesterolemia
【24h】

Meta-Analysis of Inclisiran for the Treatment of Hypercholesterolemia

机译：用于治疗高胆固醇血症的增容剂的荟萃分析

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Statin therapy is the gold standard for hypercholesterolemia. However, a significant number of patients cannot achieve their target low-density lipoprotein (LDL) levels despite a maximal dose of statin therapy, and some cannot tolerate statins at all. Approval of proprotein convertase subtilisin/kexin type 9 inhibitors has been revolutionary for those patients. However, the need for frequent injections limits patient compliance with their use. Recently, a twice-yearly injection of inclisiran, a small interfering RNA, has been shown to inhibit hepatic synthesis of proprotein convertase subtilisin/kexin type 9. However, patient randomized clinical trial has been underpowered for clinical end points, necessitating a meta-analysis of those trials. The weighted mean difference was used to describe continuous variables, and pooled risk ratios, calculated using a random effects model, were used to describe discrete variables. Data from 3 randomized clinical trials comprising 3,660 patients showed that inclisiran decreased LDL cholesterol levels by 51% (95% Confidence Interval, 48 to 53%; p < 0.001) compared with placebo. It was associated with a 24% lower major adverse cardiovascular events rate (risk ratios = 0.76; 95% Confidence Interval, 0.61 to 0.92). It also significantly decreased total cholesterol by 37%, apolipoprotein B by 41%, and non high-density lipoprotein (HDL) cholesterol by 45% (all p < 0.001). No differences were found in adverse events, abnormalities in liver function tests, or creatine kinase levels between the treatment strategies. However, a mild injection site reaction occurred more frequently in the inclisiran group. In conclusions, in patients with hypercholesterolemia, inclisiran decreased LDL level by 51% without significant adverse effects. Additionally, it was associated with a lower major adverse cardiovascular event rate. (c) 2020 Elsevier Inc. All rights reserved.
机译：他汀类药物治疗是治疗高胆固醇血症的金标准。然而，尽管使用了最大剂量的他汀类药物，仍有相当一部分患者无法达到其目标低密度脂蛋白（LDL）水平，一些患者根本无法耐受他汀类药物。前蛋白转化酶枯草杆菌素/kexin 9型抑制剂的批准对这些患者来说是革命性的。然而，频繁注射的需要限制了患者对其使用的依从性。最近，一年两次注射一种小干扰RNA inclisiran，已被证明能抑制肝脏合成前蛋白转化酶枯草杆菌蛋白酶/kexin 9型。然而，患者随机临床试验的临床终点不足，需要对这些试验进行荟萃分析。加权平均差用于描述连续变量，使用随机效应模型计算的合并风险比用于描述离散变量。来自3项随机临床试验（包括3660名患者）的数据显示，与安慰剂相比，英利司兰降低LDL胆固醇水平51%（95%置信区间，48-53%；p<0.001）。与主要心血管不良事件发生率降低24%相关（风险比=0.76；95%可信区间0.61至0.92）。它还显著降低总胆固醇37%，载脂蛋白B 41%，非高密度脂蛋白（HDL）胆固醇45%（均p<0.001）。两种治疗策略在不良事件、肝功能检查异常或肌酸激酶水平方面均未发现差异。然而，inclisiran组的注射部位反应较轻。总之，在高胆固醇血症患者中，inclisiran将LDL水平降低了51%，而没有明显的不良反应。此外，它与较低的主要心血管不良事件发生率有关。（c） 2020爱思唯尔公司版权所有。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号